Investment case
Amgen Inc.
AMGN · 73 developments mapped · last assessed 2026-09-28
Market Ontology has mapped 73 macro, policy, and market developments to Amgen Inc. since 2026-08-12. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for AMGN yet, so no modelled value is shown. The AMGN valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run AMGN on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways
Validation of novel therapeutic approaches, potential for future pipeline expansion or partnerships in cardiovascular diseases, especially given their existing cardiovascular portfolio.
· Moves probability of success pipeline, addressable market size, r&d efficiency
- Main threat
Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage
Intensified competition in the metabolic disease space, potentially diverting R&D focus and market attention from other therapeutic areas.
· Moves pipeline success rates, market share projections, r&d efficiency
- Open question
Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 on Taltz and New Launches
Competitive landscape in the immunology market. LLY's strong immunology growth, particularly with Taltz (psoriasis/psoriatic arthritis), could pose a competitive challenge to AMGN's immunology assets like Otezla and Enbrel.
· Moves market share expectations, revenue growth rate
What changed, by assumption
- 2026-09-17Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways
- 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage
- 2026-09-18Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expands
- 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverage
- 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide
- 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial of Dual GLP-1/GIP Agonist Enicepatide
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-28 | Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocation | watch | 3-12m | 0.20 |
| 2026-09-28 | Eli Lilly discontinues pipeline GLP-1 candidate following efficacy review | Bullish | 3-12m | 0.10 |
| 2026-09-28 | HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830 | watch | 1-5y | 0.20 |
| 2026-09-28 | Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise lead | mixed | 3-12m | 0.20 |
| 2026-09-28 | Eli Lilly Discontinues Early-Stage GLP-1 Candidate Following Efficacy Review | Bullish | 1-3m | 0.10 |
| 2026-09-28 | Eli Lilly Drops Experimental GLP-1 Candidate as Core Incretin Portfolio Reaches 65% of Sales | Bullish | 3-12m | 0.30 |
| 2026-09-28 | Eli Lilly Discontinues Sub-Par GLP-1 Candidate to Refocus Capital on Next-Gen Formulations | mixed | 3-12m | 0.30 |
| 2026-09-28 | Eli Lilly Drops Experimental GLP-1 Candidate Following Subpar Efficacy Data | Bullish | 3-12m | 0.40 |
| 2026-09-28 | HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugate | watch | 1-5y | 0.20 |
| 2026-09-27 | Eli Lilly Drops Experimental Obesity Candidate; Incretins Exceed 65% of Total Revenue | Bullish | 3-12m | 0.30 |
| 2026-09-27 | Eli Lilly Drops Pipeline Obesity Asset as GLP-1 Franchise Exceeds 65% Revenue | Bullish | 1-5y | 0.30 |
| 2026-09-27 | Eli Lilly discontinues developmental obesity drug over unmet efficacy threshold | watch | 3-12m | 0.30 |